End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
82.7 EUR | -5.27% |
|
+2.80% | -13.39% |
27/06 | Pfizer, BioNTech Get Positive Committee Opinion for Omicron JN.1-Adapted COVID-19 Vaccine in European Union | MT |
27/06 | Pfizer, BioNTech Get Positive CHMP Opinion for New Covid-19 Vaccine | DJ |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.39% | 19.91B | - | ||
+16.13% | 122B | B+ | ||
+19.65% | 115B | B+ | ||
+21.22% | 26.64B | B | ||
-17.47% | 16.32B | A- | ||
-45.95% | 15.52B | A- | ||
-19.28% | 15.49B | B | ||
+63.81% | 14.83B | C+ | ||
+1.94% | 13.67B | C+ | ||
+116.04% | 11.12B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BNTX Stock
- BNTX Stock
- Ratings BioNTech SE